These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 35702885)
1. Erdheim-Chester disease and vemurafenib: a review of ophthalmic presentations and clinical outcomes. Park JK; Huang LC; Kossler AL Orbit; 2023 Jun; 42(3):233-244. PubMed ID: 35702885 [TBL] [Abstract][Full Text] [Related]
2. Erdheim-Chester disease with orbital involvement: Case report and ophthalmic literature review. Merritt H; Pfeiffer ML; Richani K; Phillips ME Orbit; 2016 Aug; 35(4):221-6. PubMed ID: 27322549 [TBL] [Abstract][Full Text] [Related]
3. [Erdheim-Chester disease presenting with bilateral orbital involvement: Report of three cases]. Kiratli H; Koç I; Söylemezoğlu F J Fr Ophtalmol; 2020 Nov; 43(9):851-857. PubMed ID: 32829941 [TBL] [Abstract][Full Text] [Related]
4. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284 [TBL] [Abstract][Full Text] [Related]
5. An effective treatment in Erdheim Chester disease: vemurafenib: a case report. Bozan E; Darçın T; Yaman S; Yiğenoğlu TN; Kızıl Çakar M; Dal MS; Altuntaş F J Med Case Rep; 2023 Oct; 17(1):426. PubMed ID: 37821987 [TBL] [Abstract][Full Text] [Related]
6. Erdheim-Chester disease with bilateral orbital masses and multi-systemic symptoms: two case reports. Qiao J; Ma R; Peng X; He W World J Surg Oncol; 2023 Jul; 21(1):233. PubMed ID: 37525276 [TBL] [Abstract][Full Text] [Related]
7. BRAF-Mutated Erdheim-Chester Disease: Profound Response to Vemurafenib Visualized With Serial Multimodality Imaging. Gray JCR; Kim J; Digianvittorio M; Feeley NK; Scheel PJ; Siegelman SS; Fishman EK; Rowe SP J Natl Compr Canc Netw; 2020 Jun; 18(6):650-655. PubMed ID: 32502983 [TBL] [Abstract][Full Text] [Related]
8. Vemurafenib (BRAF Inhibitor) Therapy for Orbital Erdheim-Chester Disease. Gupta A; Yeganeh A; Rootman D; Goldberg R Ophthalmic Plast Reconstr Surg; 2017; 33(6):e138-e139. PubMed ID: 28099231 [TBL] [Abstract][Full Text] [Related]
9. Erdheim-Chester Disease With Eyelid and Orbital Involvement: A Review of Treatment Modalities at One Institution From 2014 to 2022. Sharma M; Stevens SM; Maeng MM; Nagornaya N; Bhatia RG; Wester ST Ophthalmic Plast Reconstr Surg; 2024 Sep-Oct 01; 40(5):497-503. PubMed ID: 38427815 [TBL] [Abstract][Full Text] [Related]
10. Erdheim-Chester disease: expanding the spectrum of cutaneous manifestations. Kobic A; Shah KK; Schmitt AR; Goyal G; Go RS; Guo R; Rech KL; Sartori-Valinotti JC; Br J Dermatol; 2020 Feb; 182(2):405-409. PubMed ID: 31120137 [TBL] [Abstract][Full Text] [Related]
12. Erdheim-Chester disease: a comprehensive review from the ophthalmologic perspective. Kanakis M; Petrou P; Lourida G; Georgalas I Surv Ophthalmol; 2022; 67(2):388-410. PubMed ID: 34081930 [TBL] [Abstract][Full Text] [Related]
13. Erdheim-Chester Disease: Two cases from an ophthalmic perspective. Brodie J; Zhou S; Makkuni D; Beadsmoore C; Mukhtyar C; Saada J; Bowles KM; Beigi B; Burton BJL Am J Ophthalmol Case Rep; 2020 Dec; 20():100984. PubMed ID: 33204897 [TBL] [Abstract][Full Text] [Related]
14. Hypoalphalipoproteinemia and BRAF Cohen-Aubart F; Guerin M; Poupel L; Cluzel P; Saint-Charles F; Charlotte F; Arsafi Y; Emile JF; Frisdal E; Le Goff C; Donadieu J; Amoura Z; Lesnik P; Haroche J; Le Goff W Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1913-1925. PubMed ID: 29930009 [TBL] [Abstract][Full Text] [Related]
15. FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the Oneal PA; Kwitkowski V; Luo L; Shen YL; Subramaniam S; Shord S; Goldberg KB; McKee AE; Kaminskas E; Farrell A; Pazdur R Oncologist; 2018 Dec; 23(12):1520-1524. PubMed ID: 30120160 [TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of vemurafenib in the treatment of BRAF(V600E)-mutated Erdheim-Chester disease]. Liu T; He TH; Niu N; Li J; Zhou DB; Cao XX Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):752-756. PubMed ID: 34753230 [No Abstract] [Full Text] [Related]
17. Orbital involvement in Erdheim-Chester disease. Lau WW; Chan E; Chan CW Hong Kong Med J; 2007 Jun; 13(3):238-40. PubMed ID: 17548915 [TBL] [Abstract][Full Text] [Related]
18. Dramatic Efficacy of Interferon and Vemurafenib on Psychiatric Symptoms Revealing Razanamahery J; Abdallahoui M; Chabridon G; Fromont A; Tarris G; Idbaih A; Comby PO; Godard F; Haroche J; Audia S; Bonnotte B Front Immunol; 2022; 13():918613. PubMed ID: 35874752 [TBL] [Abstract][Full Text] [Related]
19. Ophthalmologic Findings in Pediatric Erdheim-Chester Disease: A Literature Review With a Novel Case Report. Yeager LB; Grimes JM; Dal Col AK; Shah NV; Bogomolny D; Debelenko L; Marr BP Ophthalmic Plast Reconstr Surg; 2023 Sep-Oct 01; 39(5):419-426. PubMed ID: 36877575 [TBL] [Abstract][Full Text] [Related]